Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 28, 2017
Discovery and Clinical Evaluation of MK-8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release.
Journal: Journal of the American Heart Association
Published: August 27, 2016
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
Journal: Leukemia research
Published: March 15, 2016
Showing 1-3 of 3
Last Updated: 09/26/2026